Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991558 | 0.97 | CYP1A1 (0.36) | CYP1A1CYP1B1PPARGPPARAALDH1A1 | |
| SCHEMBL21991569 | 0.92 | MAOB (0.47) | PPARGPPARAPPARDPSMB5FFAR1 | |
| SCHEMBL21991902 | 0.91 | NPSR1 (0.43) | CYP1A1CYP1B1PPARGPPARAALDH1A1 | |
| SCHEMBL21991325 | 0.88 | NPSR1 (0.40) | PPARGPPARAALDH1A1MAPTPPARD | |
| SCHEMBL21991905 | 0.87 | ALDH1A1 (0.39) | PPARGPPARAALDH1A1MAPTPPARD | |
| SCHEMBL21991300 | 0.87 | NPSR1 (0.39) | PPARGPPARAALDH1A1MAPTPSMB5 | |
| SCHEMBL21991879 | 0.86 | MTNR1A (0.43) | PPARGPPARAMAPT | |
| SCHEMBL21992637 | 0.85 | PPARA (0.40) | PPARGPPARAALDH1A1CYP3A4NPSR1 | |
| SCHEMBL21992649 | 0.85 | MEN1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL21991266 | 0.84 | PPARG (0.43) | PPARGPPARAALDH1A1MAPTPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A1 2333/4885CYP1B1 2142/4885PPARG 1583/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | CYP1A1 2333/4885CYP1B1 2142/4885PPARG 1583/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CYP1A1 2333/4885CYP1B1 2142/4885PPARG 1583/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A1 2333/4885CYP1B1 2142/4885PPARG 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.